{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:09:48Z","timestamp":1768792188514,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.vph.2014.11.002","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T11:53:41Z","timestamp":1415274821000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Safety and efficacy of fibrate\u2013statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: A meta-analysis"],"prefix":"10.1016","volume":"65-66","author":[{"given":"Hye Duck","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan Gyoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Yeun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Cheol","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2014.11.002_bb0005","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diacare.25.7.1198","article-title":"Atorvastatin and micronized fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia","volume":"25","author":"Athyros","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.vph.2014.11.002_bb0010","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2014.11.002_bb0015","doi-asserted-by":"crossref","first-page":"s11","DOI":"10.1016\/S0953-6205(11)60044-7","article-title":"Fibrate induced renal insufficiency","volume":"22","author":"Beukhof","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.vph.2014.11.002_bb0020","doi-asserted-by":"crossref","first-page":"19C","DOI":"10.1016\/j.amjcard.2006.11.017","article-title":"Expert commentary: the safety of fibrates in lipid-lowering therapy","volume":"99","author":"Brown","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2014.11.002_bb0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.vph.2014.11.002_bb0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ejim.2012.05.008","article-title":"Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A2 mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity","volume":"23","author":"Constantinides","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.vph.2014.11.002_bb0035","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2014.11.002_bb0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.vph.2014.11.002_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2003.11.012","article-title":"Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia","volume":"64","author":"Durrington","year":"2004","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.vph.2014.11.002_bb0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2014.11.002_bb0055","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.amjcard.2010.07.041","article-title":"Pharmacoepidemiology safety study of fibrate and statin concomitant therapy","volume":"106","author":"Enger","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2014.11.002_bb0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0002-9149(99)00606-2","article-title":"Effect of combined fluvastatin\u2013fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia","volume":"85","author":"Farnier","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2014.11.002_bb0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10557-012-6394-0","article-title":"A review of time courses and predictors of lipid changes with fenofibric acid\u2013statin combination","volume":"26","author":"Filippatos","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.vph.2014.11.002_bb0070","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2014.11.002_bb0075","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.amjcard.2010.11.009","article-title":"Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia","volume":"107","author":"Goldberg","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2014.11.002_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.vph.2014.11.002_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/10061630-000000000-00000","article-title":"Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials","volume":"10","author":"Jones","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.vph.2014.11.002_bb0090","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2014.11.002_bb0095","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2014.11.002_bb0100","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2014.11.002_bb0105","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective sties of diseases","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vph.2014.11.002_bb0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.7326\/0003-4819-112-3-228","article-title":"Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy","volume":"112","author":"Marais","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vph.2014.11.002_bb0115","doi-asserted-by":"crossref","first-page":"1C","DOI":"10.1016\/j.amjcard.2006.11.015","article-title":"Introduction. Report of the National Lipid Association's Safety Task Force: the nonstatins","volume":"99","author":"McKenney","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2014.11.002_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ahj.2008.08.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study","volume":"157","author":"Mohiuddin","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.vph.2014.11.002_bb0125","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0021-9150(00)00379-8","article-title":"Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)","volume":"150","author":"Pauciullo","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2014.11.002_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.1990.03450010075034","article-title":"Myopathy and rhabdomyolysis associated with lovastatin\u2013gemfibrozil combination therapy","volume":"264","author":"Pierce","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2014.11.002_bb0135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10557-010-6266-4","article-title":"Efficacy and safety of rosuvastatin 5mg in combination with fenofibric acid 135mg in patients with mixed dyslipidemia \u2014 a phase 3 study","volume":"24","author":"Roth","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.vph.2014.11.002_bb0140","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0002-9149(03)00111-5","article-title":"Effects of adding fenofibrate (200mg\/day) to simvastatin (10mg\/day) in patients with combined hyperlipidemia and metabolic syndrome","volume":"91","author":"Vega","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2014.11.002_bb0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0002-9343(93)90114-5","article-title":"Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia","volume":"94","author":"Winklund","year":"1993","journal-title":"Am J Med"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114001724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114001724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T20:23:42Z","timestamp":1538079822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189114001724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":29,"alternative-id":["S1537189114001724"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2014.11.002","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of fibrate\u2013statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2014.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}